Wunder Mobility Launches Its Own Sharing Ready E-Bike Co-developed With Yadea
29.10.2021 09:30:00 EEST | Business Wire | Press release
Wunder Mobility, the international provider of software and hardware for new mobility services, has launched its first co-developed e-bike. Unveiled at the Wunder Mobility Summit 2021, the new bike has been designed in partnership with Yadea, specifically for shared use. It boasts an industry-topping range of 120km, comes with a speed of 25 km/h, and is specifically designed for European markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028006347/en/
Wunder Mobility's new e-bike has been designed in partnership with Yadea, specifically for shared use.
The e-bike’s launch follows the recent IPCC Intergovernmental Panel on Climate Change Sixth Assessment Report which drastically shows that CO2 emissions must be substantially reduced.
As an environmentally friendly mode of transport, bike-sharing is expected to grow 11% worldwide by 2025. During COVID-19, spurred on by booming consumer demand, many city authorities have increased their efforts to make their cities more bike-friendly. Initiatives include pop-up lanes and new cycleways. Political commitments to a transition to the Green Economy continue to drive investment in cycling infrastructure.
Working with Yadea, the world’s largest manufacturer of electric two-wheel vehicles, Wunder Mobility's own e-bike is a leap forward in design to help shared mobility operators capitalise on increasing opportunity. The companies are building on their long-standing relationship with Wunder Mobility’s software integrating with Yadea vehicles since 2019.
Taking shared e-bike performance to the next level
This is the first time an e-bike has been co-designed with Wunder Mobility’s technology and insight at its core. It combines Wunder Mobility’s data-driven understanding of the needs of operators and their users with Yadea’s market leadership in design and manufacturing.
With a range of 120km the e-bike far exceeds the industry average of 70-80km and is based on rider biometrics which best fit the European market. It is equipped with a motor lock and a smart lock for dual security – a rear wheel cover enclosing the locking mechanism to prevent tampering and offering space for marketing purposes. A swappable battery, firmware updates over the air and a built-in IoT connector which comes with Wunder Mobility software provide further ease of use for operators.
Gunnar Froh, Founder and Chief Executive Officer of Wunder Mobility, said:
“Cycling is one of the key solutions for reducing mobility emissions. Through our collaboration we have produced a better performing e-bike for both the operator and the cyclist. This will play a vital role in helping cities and their citizens to achieve green goals and boost wellbeing through exercise. Superior range, weight and security coupled to our powerful platform will enable more short city journeys and cleaner and healthier longer distance urban travel.”
Heidi Zang, Overseas Director at Yadea, said:
“The extensive market research, analysis and design development behind this e-bike has deepened our close collaboration with the team at Wunder Mobility. A market-dominating high range, low weight and uncomplicated maintenance sets new standards and complements the product portfolio of environmentally friendly urban mobility solutions. The simple and smooth design is unique in the sharing field, attracting consumers' attention and encouraging them to choose this e-bike.”
ENDS
Yadea:
Yadea is a global leader in developing and manufacturing electric two-wheel vehicles including electric motorcycles, electric mopeds, electric bicycles and electric kick scooters. Yadea's mission is to use its market leadership to inspire a movement towards greener travel solutions and its vision is to create world-leading electric vehicle solutions by building innovative technologies that meet and exceed international standards for safety and quality.
For more information: www.yadea.com.
Wunder Mobility:
Wunder Mobility is the global leader in software and hardware for new mobility services. The mobility tech company provides white-label solutions that enable enterprises, startups and cities worldwide to deliver sustainable, convenient and secure mobility.
100+ customers in over 900 cities on six continents use the Wunder Mobility platform to launch and scale new mobility services, manage and finance shared vehicle fleets, optimize daily operations, and improve urban planning and traffic management.
The global Wunder Mobility team, with more than 40 nationalities, consists of technology and mobility industry veterans. 50% of the team is in Product and Engineering. Wunder Mobility was founded in 2014 by Gunnar Froh and Sam Baker. The headquarters are in Hamburg, with additional locations in Dortmund and Los Angeles. For more information:
www.wundermobility.com | LinkedIn | Twitter | YouTube | Wunder Mobility Podcast
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028006347/en/
Contact information
Press contact
WunderCar Mobility Solutions GmbH
Marius Koch
Mail: press@wundermobility.com
Tel: +49 1515 339 1834
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
